VistaGen Therapeutics

$0.751
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0269 (-3.38%) Today

-$0.019 (-2.47%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell VTGN and other stocks, options, and ETFs commission-free!

About VTGN

VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. The listed name for VTGN is VistaGen Therapeutics, Inc. Common Stock.

CEO

Shawn K. Singh

Employees

Headquarters

South San Francisco, California

Founded

1998

Market Cap

43.24M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

744.49K

High Today

$0.795

Low Today

$0.726

Open Price

$0.78

Volume

653.29K

52 Week High

$1.06

52 Week Low

$0.30

Collections

VTGN Earnings

-$0.15

-$0.10

-$0.05

$0.00

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Feb 11, After Hours